Xue Jiang

505 total citations
28 papers, 368 citations indexed

About

Xue Jiang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Xue Jiang has authored 28 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Surgery. Recurrent topics in Xue Jiang's work include PARP inhibition in cancer therapy (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Advanced Radiotherapy Techniques (3 papers). Xue Jiang is often cited by papers focused on PARP inhibition in cancer therapy (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Advanced Radiotherapy Techniques (3 papers). Xue Jiang collaborates with scholars based in China, United States and United Kingdom. Xue Jiang's co-authors include Yueshuang Ke, Sarah Marrinan, Mark S. Pearce, Xianlu Zeng, Xueqing Ba, Senxiang Yan, Xu Li, Linlin Liu, Lang Pan and Fang Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xue Jiang

25 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xue Jiang China 12 115 98 87 46 41 28 368
Valentina Viggiani Italy 9 79 0.7× 80 0.8× 80 0.9× 13 0.3× 23 0.6× 17 359
Roberta Iadarola Italy 8 56 0.5× 69 0.7× 51 0.6× 19 0.4× 21 0.5× 11 252
Cristian Virgil Lungulescu Romania 11 142 1.2× 163 1.7× 43 0.5× 32 0.7× 59 1.4× 43 406
Yakun Wang China 11 147 1.3× 78 0.8× 103 1.2× 42 0.9× 114 2.8× 27 487
Min‐Woong Kang South Korea 11 32 0.3× 94 1.0× 98 1.1× 27 0.6× 107 2.6× 40 422
Kai Guo China 12 157 1.4× 73 0.7× 58 0.7× 96 2.1× 87 2.1× 32 347
Ling Han China 7 202 1.8× 110 1.1× 45 0.5× 31 0.7× 79 1.9× 28 467
António Moreira Portugal 10 156 1.4× 79 0.8× 49 0.6× 27 0.6× 68 1.7× 19 360
Ami Desai India 10 49 0.4× 54 0.6× 37 0.4× 34 0.7× 75 1.8× 15 313
Michele Cennamo Italy 12 50 0.4× 187 1.9× 70 0.8× 43 0.9× 138 3.4× 27 534

Countries citing papers authored by Xue Jiang

Since Specialization
Citations

This map shows the geographic impact of Xue Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue Jiang more than expected).

Fields of papers citing papers by Xue Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xue Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue Jiang. The network helps show where Xue Jiang may publish in the future.

Co-authorship network of co-authors of Xue Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Xue Jiang. A scholar is included among the top collaborators of Xue Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xue Jiang. Xue Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
3.
Zhou, Quanyu, Xue Jiang, Wenling Tu, et al.. (2025). Investigation into the efficiency and prognostic elements of CT-guided ¹²⁵I particle implantation for liver cancer. Cancer Imaging. 25(1). 89–89.
4.
Ma, Lan, et al.. (2024). Causal association between non-thyroidal autoimmune diseases and Graves' ophthalmopathy: A mendelian randomization study. SHILAP Revista de lepidopterología. 5(1). 66–72. 1 indexed citations
5.
Xiong, Yang, Xue Jiang, Qian Zhong, et al.. (2024). Possible sarcopenia and risk of chronic kidney disease: a four-year follow-up study and Mendelian randomization analysis. Endocrine Research. 49(3). 165–178. 4 indexed citations
6.
Jiang, Xue, Jiaojiao Zhang, Pik Kwan Lo, & Zhengwei Mao. (2023). Polyphenol‐Based Assembly Nanosystems as Multifunctional Biopharmaceutical Platform. SHILAP Revista de lepidopterología. 3(6). 10 indexed citations
7.
Jiang, Xue, Yuefei Wang, Bingsheng Li, et al.. (2023). A high responsivity, high detectivity, and high response speed MSM UVB photodetector based on SnO2 microwires. Nanoscale. 15(16). 7460–7465. 7 indexed citations
8.
Liu, Junqing, et al.. (2022). Long‐Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy. Contrast Media & Molecular Imaging. 2022(1). 3678441–3678441. 2 indexed citations
9.
Jiang, Xue, Ying Chen, Xiaoli Sun, et al.. (2021). Reduction in rectal doses of pelvic radiotherapy with excessive rectal gas extraction: a single-institution case report. Annals of Palliative Medicine. 10(6). 7062–7068. 2 indexed citations
10.
Jiang, Xue, Fang Wang, Ying Chen, & Senxiang Yan. (2021). RefineNet-based automatic delineation of the clinical target volume and organs at risk for three-dimensional brachytherapy for cervical cancer. Annals of Translational Medicine. 9(23). 1721–1721. 19 indexed citations
11.
Jiang, Xue, R. Pearson, Darren Leaning, et al.. (2020). Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. Clinical Oncology. 32(10). e177–e187. 13 indexed citations
12.
Jiang, Xue, et al.. (2019). Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients. Journal of Cancer Education. 36(3). 463–469. 17 indexed citations
13.
Ke, Yueshuang, Xiaolan Guo, Ke Wang, et al.. (2017). PARP1 promotes gene expression at the post-transcriptional level by modulating the RNA-binding protein HuR. Nature Communications. 8(1). 14632–14632. 64 indexed citations
14.
Jiang, Xue, et al.. (2017). <div>Emerging treatment options for ovarian cancer: focus on rucaparib</div>. International Journal of Women s Health. Volume 9. 913–924. 17 indexed citations
15.
Wang, Fang, et al.. (2016). Comparison of computed tomography and magnetic resonance imaging in cervical cancer brachytherapy: A systematic review. Brachytherapy. 16(2). 353–365. 20 indexed citations
16.
Jiang, Xue, Qiao Wang, & Rui Huang. (2015). Nasal Visualization on Radioiodine Whole-Body Scintigraphy Due to Benign Abnormality. Clinical Nuclear Medicine. 40(4). 340–342. 1 indexed citations
17.
Jiang, Xue, et al.. (2014). Unusual Uptake of Radioiodine in a Retroperitoneal Bronchogenic Cyst in a Patient With Thyroid Carcinoma. Clinical Nuclear Medicine. 40(5). 435–436. 12 indexed citations
18.
Marrinan, Sarah, et al.. (2014). Admission for osteoporotic pelvic fractures and predictors of length of hospital stay, mortality and loss of independence. Age and Ageing. 44(2). 258–261. 63 indexed citations
19.
Liu, Linlin, Yueshuang Ke, Xue Jiang, et al.. (2012). Lipopolysaccharide activates ERK–PARP-1–RelA pathway and promotes nuclear factor–κB transcription in murine macrophages. Human Immunology. 73(5). 439–447. 52 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026